Supernus Pharmaceuticals Stock In The News
| SUPN Stock | USD 31.20 1.61 4.91% |
Our overall analysis of Supernus Pharmaceuticals' news coverage and content from conventional and social sources shows investors' bearish mood towards Supernus Pharmaceuticals. The specific impact of Supernus Pharmaceuticals news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Supernus Pharmaceuticals' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Supernus Pharmaceuticals headlines in addition to utilizing other, more conventional financial analysis modules. Check out Supernus Pharmaceuticals Backtesting and Supernus Pharmaceuticals Hype Analysis. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.
Supernus |
Supernus Pharmaceuticals Today Top News and Investor Outlook
Supernus Pharmaceuticals Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Supernus and other traded companies coverage with news coverage. We help investors stay connected with Supernus headlines for the 26th of February to make an informed investment decision based on correlating the impacts of news items on Supernus Stock performance. Please note that trading solely based on the Supernus Pharmaceuticals hype is not for everyone as timely availability and quick action are needed to avoid losses.
Supernus Pharmaceuticals stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Supernus earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Supernus Pharmaceuticals that are available to investors today. That information is available publicly through Supernus media outlets and privately through word of mouth or via Supernus internal channels. However, regardless of the origin, that massive amount of Supernus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Supernus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Supernus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Supernus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Supernus Pharmaceuticals alpha.
Supernus Largest EPS Surprises
Earnings surprises can significantly impact Supernus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-05-03 | 2016-03-31 | 0.09 | 0.08 | -0.01 | 11 | ||
2015-08-04 | 2015-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2017-05-09 | 2017-03-31 | 0.22 | 0.19 | -0.03 | 13 | ||
2015-05-05 | 2015-03-31 | -0.01 | 0.02 | 0.03 | 300 | ||
2024-08-06 | 2024-06-30 | 0.31 | 0.36 | 0.05 | 16 | ||
2016-08-02 | 2016-06-30 | 0.13 | 0.18 | 0.05 | 38 |
Supernus Pharmaceuticals Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Supernus Pharmaceuticals Stock. The global stock market is bearish. About 62% of major world exchanges and indexes are down. See today's market update for more information.
25th of February 2025
Supernus Pharmaceuticals Beats Q4 Earnings and Revenue Estimates at zacks.com
20th of February 2025
Personalis May Report Negative Earnings Know the Trend Ahead of Next Weeks Release at finance.yahoo.com
19th of February 2025
BREAKING Supernus Pharmaceuticals, Inc. Shares Down 14 Investors Should Contact Block Levi... at globenewswire.com
10th of February 2025
Investor Optimism Abounds Supernus Pharmaceuticals, Inc. But Growth Is Lacking at simplywall.st
6th of February 2025
Supernus wins FDA approval for Parkinsons pump on fourth try at finance.yahoo.com
29th of January 2025
Supernus Pharmaceuticals exec sells 129,676 in stock - Investing.com at news.google.com
13th of December 2024
Newron and EA Pharma Announce License Agreement for Evenamide in Japan and Other Asian Ter... at businesswire.com
Supernus Pharmaceuticals Investors Sentiment
The influence of Supernus Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Supernus. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Supernus Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Supernus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Supernus Pharmaceuticals' short interest history, or implied volatility extrapolated from Supernus Pharmaceuticals options trading.
Check out Supernus Pharmaceuticals Backtesting and Supernus Pharmaceuticals Hype Analysis. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share | Quarterly Revenue Growth 0.142 | Return On Assets |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Supernus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.